PIK3CA and head and neck squamous cell carcinoma: Hedberg et al suggest that PIK3CA variations may be a clinically useful marker to identify which patients with HNSCC will benefit from NSAID use12; however, until such testing is routine, the data presented here suggest that giving daily aspirin to patients with head and neck cancer who are receiving CRT may be associated with improved survival.